Specialist · Toronto, ON
Noetic Fund
Early-stage mental health and CNS therapeutics, psychedelics included.
- Cheque
- $500k and up
- Role
- Can lead a round
- Pace
- Quiet lately
- Kind
- Specialist
- Based in
- Toronto, ON
- Founded
- 2020
- Works in
- EN
- Last deal seen
- September 2022
- Sectors
- Health and biotech
Their thesis, in full
Toronto-based pure-play fund investing in early-stage mental health and wellbeing, through a multi-modal strategy spanning novel CNS drug therapeutics, psychedelic-assisted therapies, digital health and medical devices. Noetic closed Fund I in 2020 and launched Fund II in 2021 with a $200M target. Disciplined thematic approach in an emerging category where clinical science is advancing rapidly. The team brings long-term conviction on psychedelic medicine and pairs cheques with deep network access in regulatory affairs, clinical operations and pharma partnerships. Built for biotech founders attacking neurology and mental health markets with novel mechanisms of action.
What they bring past the cheque
- Psychedelic medicine depth
- CNS therapeutics expertise
- Clinical and regulatory support
- Long-term conviction
- Pure-play network
Questions they usually ask
Have an answer ready for each one before the first call.
- What clinical milestones unlock the next valuation step for your asset?
- How does your IP defend against fast-following compounds and dosing variants?
- What is your reimbursement and insurance coverage hypothesis at launch?
Follow-on
Noetic reserves capital for clinical milestone follow-ons and syndicates seed and Series A rounds with life sciences investors (Angelini Lumira Biosciences Fund, TIAP). Long-duration support is the explicit posture given regulatory timelines.
Who to talk to
- Sa'ad ShahManaging PartnerLinkedIn ↗
- Sri Teja MullapudiPrincipal, Fund Investments, Scientific LeadLinkedIn ↗
- Richard CheungGeneral CounselLinkedIn ↗
- Yee TanPrincipal, Finance, OperationsLinkedIn ↗
- Victor MifsudHead of Real World EvidenceLinkedIn ↗
- Jeffrey BeckerVenture PartnerLinkedIn ↗
- Marine MallinsonVenture AdvisorLinkedIn ↗
- Craig HippernAdvisorLinkedIn ↗
Portfolio
Names they back, most notable first.
- Beckley PsytechExit · 2025
- DAMONA PharmaceuticalsSeed · 2022
- CaaMTechSeries A · 2021
- Alexander Shulgin Research InstituteSeed · 2021
- Apollo Neuroscience
- COMPASS PathwaysExit
- MindMedExit
- Bexson Biomedical
- CybinExit
- EleusisExit
- NuminusExit
Often in the same rounds
Investors seen alongside them in past rounds.
- Angelini Lumira Biosciences Fund
- Toronto Innovation Acceleration Partners
Similar investors
Overlapping sectors and stages. Useful to build a list of 10 to 20 names for one round.
See how they fit your round
Set your stage, sector and amount once. Fractal App tells you if Noetic Fund can lead it, tracks every follow-up, and counts the days of silence. Free, no card.
Open in the app →